Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 141
- Registration Number
- NCT03889444
- Locations
- 🇺🇸
Clinical Trials Registry Team, Irvine, California, United States
Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)
- Conditions
- Glaucoma
- Interventions
- Device: XEN GroupProcedure: Phacoemulsification
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 174
- Registration Number
- NCT03868254
- Locations
- 🇺🇸
Clinical Trials Registry Team, Irvine, California, United States
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
- Conditions
- Masseter Muscle Prominence
- Interventions
- Biological: OnabotulinumtoxinADrug: Normal saline
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 150
- Registration Number
- NCT03861936
- Locations
- 🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸DeNova Research, Chicago, Illinois, United States
🇺🇸Baumann Cosmetic and Research Institute, Miami, Florida, United States
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Other: Vehicle
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 427
- Registration Number
- NCT03857542
- Locations
- 🇺🇸
Advanced Vision Care, Los Angeles, California, United States
🇺🇸South Florida Vision Center, Fort Lauderdale, Florida, United States
🇺🇸Eye Center South, Dothan, Alabama, United States
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
- Conditions
- Chronic Migraine
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 778
- Registration Number
- NCT03855137
- Locations
- 🇫🇷
AP-HM - Hopital de la Timone /ID# 236285, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸DiscoveResearch, Inc /ID# 236274, Bryan, Texas, United States
🇺🇸Abington Neurological Associates - Abington /ID# 236258, Abington, Pennsylvania, United States
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
- Conditions
- Glaucoma
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 28
- Registration Number
- NCT03852810
- Locations
- 🇨🇦
Toronto Ophthalmic Research Innovation Centre, Inc, Toronto, Ontario, Canada
🇩🇪University of Tübingen, Tübingen, Germany
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom
Evaluation of Age-Related Skin Changes
- Conditions
- Age-related Skin Changes
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 100
- Registration Number
- NCT03842566
- Locations
- 🇫🇷
Dermscan-Pharmascan, Villeurbanne, France
Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease
- Conditions
- Dry Eye Syndromes
- Interventions
- Device: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 14
- Registration Number
- NCT03827564
- Locations
- 🇺🇸
Baylor College of Medicine - Department of Ophthalmology, Houston, Texas, United States
Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Other: Vehicle
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 323
- Registration Number
- NCT03804268
- Locations
- 🇺🇸
American Institute of Research, Los Angeles, California, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Danbury Eye Physicians and Surgeons P.C., Danbury, Connecticut, United States
A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation
- Conditions
- Lip Augmentation
- Interventions
- Device: Juvéderm® VOLIFT™ with Lidocaine
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 60
- Registration Number
- NCT03796728
- Locations
- 🇵🇹
Clinica Milenio, Lisbon, Portugal
🇵🇹Clínica Secret Beauty, Lisbon, Portugal
🇬🇧Medical and Cosmetic Clinic, Edinburgh, United Kingdom